Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IONS

Ionis Pharmaceuticals Inc

Dec 20 • 04:00PM ET

35.63

Dollar change +0.04
Percentage change 0.11	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD NBIX ALNY PRTA ARWR SRPT FOLD

| Held by: VTI VB VXF VBK XBI ARKG IBB IWP SCHA IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.44	Insider Own	7.82%	Shs Outstand	157.81M	Perf Week	-2.68%
Market Cap	5.63B	Forward P/E	-	EPS next Y	-3.70	Insider Trans	-0.31%	Shs Float	145.55M	Perf Month	0.65%
Income	-358.55M	PEG	-	EPS next Q	-1.11	Inst Own	98.05%	Short Float	7.18%	Perf Quarter	-14.82%
Sales	803.56M	P/S	7.01	EPS this Y	-36.78%	Inst Trans	9.24%	Short Ratio	7.09	Perf Half Y	-20.26%
Book/sh	4.20	P/B	8.49	EPS next Y	-5.67%	ROA	-11.92%	Short Interest	10.45M	Perf Year	-26.28%
Cash/sh	15.71	P/C	2.27	EPS next 5Y	35.30%	ROE	-73.33%	52W Range	33.33 - 54.44	Perf YTD	-29.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-13.78%	52W High	-34.56%	Beta	0.35
Dividend TTM	-	Quick Ratio	8.82	Sales past 5Y	13.97%	Gross Margin	95.93%	52W Low	6.90%	ATR (14)	1.47
Dividend Ex-Date	-	Current Ratio	8.91	EPS Y/Y TTM	14.63%	Oper. Margin	-46.08%	RSI (14)	42.74	Volatility	4.73% 3.99%
Employees	927	Debt/Eq	3.00	Sales Y/Y TTM	30.63%	Profit Margin	-44.62%	Recom	1.68	Target Price	60.80
Option/Short	Yes / Yes	LT Debt/Eq	2.93	EPS Q/Q	8.09%	Payout	-	Rel Volume	2.76	Prev Close	35.59
Sales Surprise	3.42%	EPS Surprise	15.61%	Sales Q/Q	-7.21%	Earnings	Nov 06 BMO	Avg Volume	1.47M	Price	35.63
SMA20	-2.66%	SMA50	-4.82%	SMA200	-15.02%	Trades		Volume	4,061,209	Change	0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64
Mar-01-22	Initiated	Citigroup	Sell	$26
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform	$40 → $30
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform

Show Previous Ratings

Dec-20-24 07:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
03:09PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:23AM	FDA approves Ionis TRYNGOLZA for FCS treatment (Pharmaceutical Technology)
07:24AM	FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood (Benzinga)
06:00AM	Ionis gets a milestone approval; Another top FDA official to step down (BioPharma Dive)
06:28PM	Loading…
Dec-19-24 06:28PM	TRYNGOLZA (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet (PR Newswire)
Dec-11-24 09:55AM	How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% (Zacks)
Dec-08-24 05:55PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Dec-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-05-24 07:35AM	Theratechnologies enters exclusive licensing agreement with Ionis (TipRanks)
Nov-27-24 12:00PM	Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-21-24 05:22PM	Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-19-24 07:08PM	Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-18-24 09:35AM	Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks (Zacks)
07:05AM	Loading…
Nov-07-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
05:15AM	Ionis announces design for Phase III trial of Angelman syndrome therapy (Clinical Trials Arena)
04:26AM	Q3 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com)
Nov-06-24 09:45AM	Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? (Motley Fool)
09:30AM	Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:07AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome (PR Newswire)
07:00AM	Ionis reports third quarter 2024 financial results (PR Newswire)
Nov-04-24 09:44AM	Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE (PR Newswire)
09:16AM	Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Oct-30-24 10:01AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-24 07:05AM	Ionis to hold third quarter 2024 financial results webcast (PR Newswire)
Oct-22-24 07:41AM	EU CHMP recommends AstraZeneca and Ionis Wainzua for ATTRv-PN (Pharmaceutical Technology)
02:08AM	Loading…
Oct-21-24 02:08AM	WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (PR Newswire)
Oct-09-24 04:11PM	Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds (Insider Monkey)
Oct-08-24 07:30AM	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA (GlobeNewswire)
Oct-03-24 07:00AM	New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (PR Newswire)
Oct-01-24 06:59PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease (PR Newswire)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-09-24 09:10PM	Ionis announces pricing of $500.3 million public offering (PR Newswire) -12.29%
04:20PM	Ionis announces proposed public offering of common stock (PR Newswire)
Sep-04-24 08:00AM	Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations (GlobeNewswire)
07:30AM	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA (GlobeNewswire)
Aug-28-24 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Aug-15-24 09:15AM	Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth? (Zacks)
Aug-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-06-24 11:34PM	Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary (GuruFocus.com)
Aug-02-24 01:32PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:54AM	Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises (Zacks)
04:34AM	Q2 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 10:00AM	Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:20AM	Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports second quarter 2024 financial results (PR Newswire)
Jul-31-24 09:00AM	Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx System for Administration of nusinersen (PR Newswire)
Jul-25-24 10:02AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-23-24 09:53AM	Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study (Zacks)
07:03AM	Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug (Clinical Trials Arena)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily) +5.83%
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
07:00AM	Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome (PR Newswire)
Jul-19-24 09:56AM	Ionis (IONS) Completes Enrolment for Rare Disease Drug Study (Zacks)
08:24AM	Ionis to hold second quarter 2024 financial results webcast (PR Newswire)
06:32AM	Ionis completes subject enrolment in Alexander disease treatment trial (Clinical Trials Arena)
Jul-18-24 07:00AM	Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease (PR Newswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jul-08-24 07:05AM	Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome (PR Newswire)
Jun-26-24 12:56PM	FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen (Zacks)
Jun-25-24 06:55AM	Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed (PR Newswire) +5.19%
06:30AM	Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks)
Jun-19-24 12:11PM	Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug (Zacks)
Jun-18-24 07:00AM	Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema (PR Newswire)
Jun-17-24 04:09PM	Ionis to present at TD Cowen Genetic Medicines & RNA Summit (PR Newswire)
Jun-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 12:25PM	Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder (Benzinga)
07:00AM	Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema (PR Newswire)
May-28-24 07:00AM	Ionis to hold donidalorsen Phase 3 data webcast (PR Newswire)
May-23-24 07:00AM	New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) (PR Newswire)
May-17-24 10:10AM	Ionis (IONS), Biogen Down on Ending Development of ALS Drug (Zacks)
May-16-24 12:46PM	Top Stock Movers Now: Walmart, Canada Goose, Deere, and More (Investopedia)
10:54AM	Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study (MT Newswires)
08:50AM	Biogen, Ionis to Cease BIIB105 ALS Investigational Drug Development Following Phase 1/2 Trial Results (MT Newswires)
08:05AM	Biogen, Ionis shelve ALS drug following study failure (BioPharma Dive)
07:51AM	REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug (Reuters)
07:37AM	Biogen, Ionis will discontinue development of their ALS drug (Reuters)
07:30AM	Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (PR Newswire)
07:30AM	Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis (GlobeNewswire)
07:00AM	Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome (PR Newswire)
May-15-24 07:05AM	Ionis to host 2024 virtual Annual Meeting of Stockholders (PR Newswire)
May-13-24 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 06:30AM	The 3 Most Undervalued Pharma Stocks to Buy in May 2024 (InvestorPlace)
May-08-24 03:15PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:59AM	Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating (MT Newswires)
10:39AM	Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss (Zacks)
05:20AM	Q1 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ... (GuruFocus.com)
May-07-24 05:02PM	Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing (MT Newswires)
04:43PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:30AM	Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:07AM	Ionis Pharmaceuticals Q1 Net Loss Widens as Revenue Falls (MT Newswires)
07:07AM	Ionis Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swayze Eric	EVP Research	Nov 12 '24	Sale	37.92	1,194	45,278	33,713	Nov 14 05:30 PM
Monia Brett P	Chief Executive Officer	Nov 12 '24	Sale	38.05	6,630	252,294	167,393	Nov 14 05:30 PM
LOSCALZO JOSEPH	Director	Nov 12 '24	Sale	37.86	13,508	511,426	32,251	Nov 14 05:30 PM
Monia Brett P	Officer	Nov 12 '24	Proposed Sale	38.89	6,629	257,774		Nov 12 04:17 PM
Swayze Eric	Officer	Nov 12 '24	Proposed Sale	38.88	1,194	46,422		Nov 12 04:16 PM
LOSCALZO JOSEPH	Officer	Nov 12 '24	Proposed Sale	38.88	13,508	525,152		Nov 12 04:15 PM
Swayze Eric	EVP Research	Oct 15 '24	Option Exercise	0.00	125	0	210	Oct 17 06:42 PM
Swayze Eric	EVP Research	Oct 16 '24	Sale	38.31	53	2,031	157	Oct 17 06:42 PM
Geary Richard S	EVP, Chief Development Officer	Aug 29 '24	Sale	49.63	331	16,428	84,823	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 28 '24	Sale	49.16	320	15,731	85,154	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 05 '24	Sale	48.00	2,430	116,640	85,508	Aug 06 05:27 PM
Geary Richard S	Executive Vice President, Chie	Aug 05 '24	Proposed Sale	49.13	3,128	153,678		Aug 05 04:11 PM
WENDER JOSEPH H	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	132,756	Jul 17 05:03 PM
PARSHALL B LYNNE	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	87,265	Jul 17 05:03 PM
LOSCALZO JOSEPH	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	45,759	Jul 17 05:03 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Option Exercise	24.42	12,000	293,040	12,000	Jul 17 05:02 PM
KLEIN JOSEPH III	Director	Jul 16 '24	Sale	50.00	12,000	600,000	0	Jul 17 05:02 PM
HERMAN JOAN E	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	42,007	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	17,353	Jul 17 05:02 PM
Diaz Allene M.	Director	Jul 16 '24	Sale	49.49	1,637	81,019	15,716	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jul 15 '24	Option Exercise	0.00	4,677	0	151,934	Jul 17 05:02 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Option Exercise	35.53	16,000	568,480	163,257	Jun 20 05:52 PM
BERTHELSEN SPENCER R	Director	Jun 17 '24	Sale	40.29	16,000	644,640	147,257	Jun 20 05:52 PM
WENDER JOSEPH H	Director	May 09 '24	Option Exercise	35.53	16,000	568,480	128,079	May 13 05:25 PM
KLEIN JOSEPH III	Director	May 03 '24	Sale	42.71	6,000	256,277	0	May 07 04:55 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '24	Option Exercise	0.00	10,838	0	23,637	Apr 17 05:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '24	Sale	41.60	4,006	166,641	19,631	Apr 17 05:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '24	Option Exercise	0.00	1,875	0	47,061	Apr 17 05:16 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '24	Sale	41.66	905	37,698	46,156	Apr 17 05:16 PM
Monia Brett P	Chief Executive Officer	Feb 16 '24	Sale	44.49	387	17,219	173,751	Feb 16 07:47 PM
Swayze Eric	EVP Research	Jan 31 '24	Sale	52.00	10,773	560,196	32,516	Feb 02 07:55 PM
Swayze Eric	EVP Research	Feb 02 '24	Sale	49.56	1,907	94,513	34,324	Feb 02 07:55 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Feb 02 '24	Sale	49.59	2,071	102,701	49,812	Feb 02 07:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 02 '24	Sale	49.67	1,961	97,410	48,661	Feb 02 07:55 PM
Monia Brett P	Chief Executive Officer	Feb 02 '24	Sale	49.37	23,501	1,160,303	174,138	Feb 02 07:55 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Feb 02 '24	Sale	49.54	2,125	105,272	92,905	Feb 02 07:55 PM
Geary Richard S	EVP, Chief Development Officer	Feb 02 '24	Sale	50.04	1,961	98,135	87,334	Feb 02 07:54 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Feb 02 '24	Sale	49.60	2,125	105,404	35,825	Feb 02 07:54 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 02 '24	Sale	49.52	1,853	91,752	79,079	Feb 02 07:54 PM
Monia Brett P	Chief Executive Officer	Jan 25 '24	Sale	51.75	2,285	118,249	151,851	Jan 29 05:34 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 25 '24	Sale	51.75	6,450	333,788	46,802	Jan 29 05:34 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 16 '24	Option Exercise	0.00	15,062	0	39,374	Jan 18 06:07 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 17 '24	Sale	50.42	5,564	280,520	33,810	Jan 18 06:07 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '24	Option Exercise	0.00	20,641	0	60,996	Jan 18 05:59 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 17 '24	Sale	50.42	7,744	390,429	53,252	Jan 18 05:59 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '24	Option Exercise	0.00	12,080	0	49,079	Jan 18 05:55 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 17 '24	Sale	50.42	4,497	226,725	44,582	Jan 18 05:55 PM
Swayze Eric	EVP Research	Jan 16 '24	Option Exercise	0.00	21	0	94	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 16 '24	Option Exercise	0.00	17,069	0	49,585	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 17 '24	Sale	50.42	6,296	317,425	43,289	Jan 18 05:49 PM
Swayze Eric	EVP Research	Jan 17 '24	Sale	50.42	9	454	85	Jan 18 05:49 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '24	Option Exercise	0.00	15,162	0	53,332	Jan 18 05:48 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 17 '24	Sale	50.42	5,482	276,386	47,850	Jan 18 05:48 PM
Monia Brett P	Chief Executive Officer	Jan 16 '24	Option Exercise	0.00	68,084	0	186,195	Jan 18 05:48 PM
Monia Brett P	Chief Executive Officer	Jan 17 '24	Sale	50.42	32,059	1,616,319	154,136	Jan 18 05:48 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '24	Option Exercise	0.00	22,487	0	99,573	Jan 18 05:48 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 17 '24	Sale	50.42	8,683	437,771	90,890	Jan 18 05:48 PM
Geary Richard S	EVP, Chief Development Officer	Jan 16 '24	Option Exercise	0.00	19,852	0	92,813	Jan 18 05:47 PM
Geary Richard S	EVP, Chief Development Officer	Jan 17 '24	Sale	50.42	7,338	369,960	85,475	Jan 18 05:47 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '24	Option Exercise	0.00	18,314	0	84,068	Jan 18 05:44 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 17 '24	Sale	50.42	6,745	340,063	77,323	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '24	Option Exercise	0.00	1,353	0	2,204	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '24	Option Exercise	0.00	3,688	0	14,259	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17 '24	Sale	50.42	1,460	73,609	12,799	Jan 18 05:44 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17 '24	Sale	50.42	564	28,435	1,640	Jan 18 05:44 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 12 '24	Option Exercise	32.60	8,000	260,800	46,170	Jan 17 08:51 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 12 '24	Sale	53.50	8,000	427,999	38,170	Jan 17 08:51 PM
Swayze Eric	EVP Research	Dec 28 '23	Option Exercise	47.34	27,100	1,282,914	59,616	Jan 02 05:54 PM
Swayze Eric	EVP Research	Dec 28 '23	Sale	50.19	27,100	1,360,081	32,516	Jan 02 05:54 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Dec 28 '23	Option Exercise	47.34	45,225	2,140,952	120,884	Jan 02 05:54 PM
Birchler Brian	EVP, Corp and Development Ops	Dec 28 '23	Option Exercise	47.34	11,500	544,410	48,028	Jan 02 05:54 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Dec 26 '23	Option Exercise	47.34	20,825	985,856	61,180	Dec 28 07:18 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Dec 26 '23	Sale	51.46	20,825	1,071,717	40,355	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 27 '23	Option Exercise	47.34	50,000	2,367,000	132,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 28 '23	Option Exercise	47.34	42,525	2,013,134	125,113	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 26 '23	Option Exercise	47.34	25,113	1,188,849	107,701	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 27 '23	Sale	50.23	50,000	2,511,515	82,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 28 '23	Sale	50.19	42,525	2,134,223	82,588	Dec 28 07:18 PM
PARSHALL B LYNNE	Director	Dec 26 '23	Sale	51.46	25,113	1,292,390	82,588	Dec 28 07:18 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Dec 26 '23	Option Exercise	47.34	25,000	1,183,500	61,052	Dec 28 07:18 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Dec 26 '23	Sale	51.46	25,000	1,286,575	36,052	Dec 28 07:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IONS

Ionis Pharmaceuticals Inc

Upgrade your FINVIZ experience